Tokyo Japan 1988 | 90 | 6.7 | gG2 Immunoblot | 30 |
Padua Italy 1985–6 | NK | 8.4 | gG2 Immunoblot | 12 |
Seville Spain 1985–6 | NK | 9.7 | gG2 Immunoblot | 12 |
London England 1980–1 | 3553 | 10 | ELISA* | 31 |
Birmingham Alabama USA (whites, private practice) 1985 | NK | 11.4 | gG2 Immunoblot | 12 |
Sydney Australia 1995–8 | 2616 | 12.5 | gG2 ELISA/WB | Present study |
Taiwan 1986–7 | NK | 13.5 | gG2 Immunoblot | 12 |
Sydney, Australia 1984–5 | 229 | 14.5 | gG2 ELISA | 11 |
Helsinki, Finland 1988–9 | 997 | 16.0 | gG2 ELISA | 24 |
Stanford USA† | 1580 | 16.5 | gG2 ELISA | 13 |
Stockholm, Sweden 1969 | 941 | 17 | gG2 ELISA | 23 |
Lyons, France 1986 | NK | 17.3 | gG2 Immunodot | 12 |
Reykjavik, Iceland 1985 | NK | 18.8 | gG2 ELISA | 12 |
Malmo, Sweden 1970–3 | 941 | 21 | gG2 ELISA | 32 |
Malmo, Sweden 1987 | 294 | 21 | gG2 ELISA | 32 |
Malmo, Sweden 1990–1 | 1190 | 21 | gG2 ELISA | 32 |
Malmo, Sweden 1986–9 | 562 | 25 | gG2 ELISA | 32 |
Seattle, USA 1989–93 | 8538 | 28.5 | WB | 6 |
Stockholm, Sweden 1983 | 1759 | 32 | gG2 ELISA | 23 |
Stockholm, Sweden 1989 | 1000 | 32 | gG2 ELISA | 23 |
Stanford, USA 1991 | 277 | 32 | gG2 ELISA | 19 |
Los Angeles, USA 1985–8 | 1355 | 32 | WB | 14 |
Atlanta, USA (whites) 1984–5 | NK | 34.9 | gG2 Immunoblot | 12 |
Sao Paulo Brazil (low and middle class) 1988–9 | 455 | 36 | ELISA and WB | 33 |
Seattle, USA 1990 | 201 | 37.8 | WB | 15 |
Sao Paulo, Brazil (very low income) 1988–9 | 200 | 42 | ELISA and WB | 33 |
Atlanta, USA (blacks) 1984–5 | NK | 53.4 | gG2 Immunoblot | 12 |